Lepromatous Leprosy: Nasal Manifestations and Treatment with Minocycline

1992 ◽  
Vol 101 (3) ◽  
pp. 261-264 ◽  
Author(s):  
Anil K. Lalwani ◽  
Thomas A. Tami ◽  
Robert H. Gelber
Keyword(s):  
Side Effects ◽  
Clinical Presentation ◽  
Lepromatous Leprosy ◽  
Diagnosis And Treatment ◽  
Traditional Therapy ◽  
Tetracycline Antibiotic ◽  
Nasal Symptoms ◽  
Minocycline Hydrochloride ◽  
New Treatment

Nasal involvement in lepromatous leprosy is universal and occurs early in the course of the disease. Nasal symptoms include obstruction, crusting, bleeding, and hyposmia. Traditional therapy with dapsone, rifampin, and clofazimine is limited by its cost and toxicity. Minocycline hydrochloride, a tetracycline antibiotic with limited side effects, is promising as a new treatment for leprosy. A case is presented that highlights the clinical presentation, diagnosis, and treatment of lepromatous leprosy.

scholarly journals Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment

2014 ◽  
Vol 89 (6) ◽  
pp. 865-877 ◽  
Author(s):  
Marcos Vinícius Clarindo ◽  
Adriana Tomazzoni Possebon ◽  
Emylle Marlene Soligo ◽  
Hirofumi Uyeda ◽  
Roseli Terezinha Ruaro ◽  
...  
Keyword(s):  
Clinical Presentation ◽  
Dermatitis Herpetiformis ◽  
Diagnosis And Treatment

Methionine Synthase Deficiency: Variable Clinical Presentation And Benefit Of Early Diagnosis And Treatment

2021 ◽  
Author(s):  
Kimberly A. Kripps ◽  
Leighann Sremba ◽  
Austin A. Larson ◽  
Johan L.K. Van Hove ◽  
Hoanh Nguyen ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Clinical Presentation ◽  
Methionine Synthase ◽  
Diagnosis And Treatment ◽  
Variable Clinical Presentation

scholarly journals Thromboembolic Conditions, Aetiology Diagnosis and Treatment in Dogs and Cats

2010 ◽  
Vol 79 (3) ◽  
pp. 497-508 ◽  
Author(s):  
Filip Konečný
Keyword(s):  
Veterinary Medicine ◽  
Clinical Presentation ◽  
Medical Condition ◽  
Definitive Diagnosis ◽  
Diagnosis And Treatment ◽  
Window Of Opportunity ◽  
Timely Manner ◽  
Human Counterpart ◽  
Life Threatening ◽  
Diagnostic Capabilities

In veterinary medicine, thrombo-embolism (TE) is an under-appreciated medical condition that requires immediate recognition. Since TE is multifactorial and its mode of presentation may vary, veterinarians face great difficulties in making a definitive diagnosis in a timely manner. In addition, most of the underlying conditions that give rise to TE are life-threatening and an aggressive diagnostic and therapeutic approach is required. Not only does the diagnosis and treatment of this condition require the collaboration of many specialties, the costs of therapy can be excessive with a high risk of recurrence. As such, owners have to be thoroughly informed before the therapy commences. While TE has been well-characterized in humans and is associated with significant morbidity and mortality, little information of similar quality is available in veterinary medicine. In addition, TE in animals is distinct from its human counterpart and we cannot simply adapt what is known from human clinical trials. With the promise of improvements in imaging modalities that improve our diagnostic capabilities, the window of opportunity to treat TE increases. This article focuses on aetiology, clinical presentation, diagnosis, and treatment of dogs and cats affected by TE.

scholarly journals Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

2021 ◽  
Author(s):  
Peter Wolf ◽  
Thomas Scherer
Keyword(s):  
Clinical Practice ◽  
Side Effects ◽  
Immune Checkpoint Inhibitor ◽  
Clinical Presentation ◽  
Checkpoint Inhibitor ◽  
Clinical Care ◽  
Short Review ◽  
Current Clinical Practice ◽  
Routine Clinical Care ◽  
Adequate Management

SummaryGiven the growing use of immune checkpoint inhibitor (ICI) therapy in oncology, the prevalence of endocrine side effects is rapidly increasing. As clinicians are nowadays frequently confronted with these side effects in routine clinical care, awareness, better knowledge of endocrine irAEs and their clinical presentation and diagnosis is crucial for an adequate management. In this short-review we give a compact overview of the recent recommendations for the management of endocrine irAE related to ICIs and highlight difficulties and uncertainties in current clinical practice.

scholarly journals Skin care physicians insight on epidemiological patterns, diagnosis and treatment modalities for female pattern hair loss

2020 ◽  
Vol 7 (1) ◽  
pp. 11
Author(s):  
Krishna Rajesh Kilaru ◽  
Suhasini Attada ◽  
Pooja Munnangi ◽  
Manogna Chowdary Kilaru
Keyword(s):  
Side Effects ◽  
Hair Loss ◽  
Treatment Guidelines ◽  
Age Of Onset ◽  
Platelet Rich Plasma ◽  
Diagnosis And Treatment ◽  
Treatment Modalities ◽  
Common Side Effect ◽  
Medication Cost ◽  
Female Pattern Hair Loss

<p class="abstract"><strong>Background:</strong> Female pattern hair loss (FPHL) is a common cause of hair loss in women characterized by a diffuse reduction in hair density over the crown and frontal scalp with retention of the frontal hairline. The underlying pathophysiology is multifactorial. There are no universally agreed treatment guidelines available. The objective of the study was to understand the diagnosis and treatment pattern of female pattern hair loss and the role of minoxidil topical formulation and its combination in the management of FPHL.</p><p class="abstract"><strong>Methods: </strong>Predesigned questionnaire on FPHL was prepared based on review of literature and was filled by 80 consultant dermatologists. Recorded data was statistically analyzed.</p><p class="abstract"><strong>Results: </strong>Common age of onset of FPHL was between 20 to 30 years. Majority (96.25%) have reported FPHL in association with psychological morbidity. The most preferred treatment in mild and severe FPHL was minoxidil 5% and platelet rich plasma (PRP) plus minoxidil respectively. Most dermatologists (47.5%) treated with minoxidil for over 6 months. Majority (27.5%) reported flaking as the most common side effect with minoxidil followed by dryness, scalp irritation and itching. Majority (27.5%) observed that long treatment duration was contributing to non-compliance followed by medication cost and side effects. Majority of the dermatologists (90%) felt the need for treatment guidelines in the current Indian scenario.</p><p class="abstract"><strong>Conclusions: </strong>Minoxidil was the most common preferred treatment for mild and severe FPHL. PRP is the most common choice of combination therapy with minoxidil. Minimizing side effects, patient education and universal treatment guidelines can help manage FPHL better.  </p>

Mirabegron: new treatment for OAB with fewer side-effects

Prescriber ◽  
2013 ◽  
Vol 24 (13-16) ◽  
pp. 39-42
Author(s):  
Steve Chaplin ◽  
Christopher Chapple
Keyword(s):  
Side Effects ◽  
New Treatment

Nano strategies in diagnosis and treatment of inflammatory Hyperlagesia

2021 ◽  
Vol 06 ◽  
Author(s):  
Atul R Chopade ◽  
Suraj N. Mali ◽  
Pramod A Patil
Keyword(s):  
Pain Management ◽  
Side Effects ◽  
Drug Carrier ◽  
Unmet Need ◽  
Diagnosis And Treatment ◽  
Systematic Analysis ◽  
Probable Answer ◽  
Anti Inflammatory ◽  
Nano Science ◽  
Effective Diagnosis

Background: There is an unmet need for effective diagnosis and treatment of chronic inflammatory pain and subsequent hypersensitivity (hyperalgesia). The nanotechnology and nano drug delivery could be a probable answer to solve this problem; this novel technique will surely take diagnosis of pain and anti-inflammatory therapy to newer heights offering faster pain relief to the patient. Objective: This study aims to collect more information about aspects of nanotechnology based applications towards pain management. Methods: A systemic search has been carried out using PubMed, Google Scholar, CNKI, etc. for relevant articles. Results and Conclusions: The article reviews possible application of nano science for betterment of anti-inflammatory therapy, which may help pain researchers. Our systematic analysis of previous studies showed that, with the ease of nanotechnology, we can effectively lower down the side effects and tolerance associated with current pain management systems. Advance nanomaterial based therapies will undoubtedly reduce the time span associated along with fewer side effects. By merging nanotechnology aspects along with drug carrier systems, we can effectively design such systems with inherent properties to treat pain.

scholarly journals Ticagrelor-Related Severe Dyspnoea: Mechanisms, Characteristic Features, Differential Diagnosis and Treatment

2020 ◽  
Vol 13 ◽  
pp. 117954762095663 ◽  
Author(s):  
Alicja Krakowiak ◽  
Jakub Kuleta ◽  
Iwona Plech ◽  
Maciej Zarębiński ◽  
Małgorzata Wojciechowska ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Side Effects ◽  
Stent Implantation ◽  
Diagnosis And Treatment ◽  
Antiplatelet Drug ◽  
Number Of Patients ◽  
Characteristic Features ◽  
Severe Dyspnoea ◽  
The Way

With a growing number of patients on ticagrelor therapy after stent implantation, we observe many cases of side effects of the drug, mostly dyspnoea and bradycardia. In our article we present 2 patients, in which the symptoms were particularly severe. Then we describe possible mechanisms of these complications, explain how to carry out differential diagnosis, discuss when to switch ticagrelor to other antiplatelet drug and finally we present the way to deal with the symptoms.

Sign in / Sign up

Export Citation Format

Share Document